Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema
Purpose This pilot study aims to comprehensively evaluate the effects of sub-Tenon’s injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM). Methods This retrospective study analyzed changes...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2024-02, Vol.262 (2), p.449-456 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 456 |
|---|---|
| container_issue | 2 |
| container_start_page | 449 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 262 |
| creator | Sotani-Ogawa, Rei Kusuhara, Sentaro Hirota, Yushi Kim, Kyung Woo Matsumiya, Wataru Ogawa, Wataru Nakamura, Makoto |
| description | Purpose
This pilot study aims to comprehensively evaluate the effects of sub-Tenon’s injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM).
Methods
This retrospective study analyzed changes in glycemic control in 20 patients with type 2 mellitus and DME following single STTA (20 mg/0.5 mL) using The FreeStyle Libre Pro system. Professional CGM provides core CGM metrics such as the percentage of time that glucose levels fall within a target range and include the time in range (TIR) (70–180 mg/dL), time above range (TAR) (> 180 mg/dL), and time below range (TBR) ( |
| doi_str_mv | 10.1007/s00417-023-06275-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10844153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2922307187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-d714372606fd5f41083ae7a1688df85a26577fed35a860840b0a3f637abd47cf3</originalsourceid><addsrcrecordid>eNp9kc2KFDEUhQtRnHb0BVxIwI2b0pufSjIrkcZRYcDNCLMLqdRNm6YqaZMqpReCrzGv55OYtsfxZ-EqkHzn3HtymuYxhecUQL0oAIKqFhhvQTLVtfs7zYoK3rUK2NXdZgWK0VZzdnXSPChlC5XnHb3fnHClpZBcrpqv6xTnEJe0FLIZF5cKkinFMKcc4oZMOOfgCvFpHNOXw01Z-vYSY4rfv10XEuIW3RxSJMmTitrJhZjGFJFYh3M1GrCKMxmC7XEOjkzWLaPNBAec7MPmnrdjwUc352nz4fz15fpte_H-zbv1q4vWCQVzO6iaSjEJ0g-dFxQ0t6gslVoPXneWyU4pjwPvrJagBfRguZdc2X4Qynl-2rw8-u6WfsLBYZyzHc0uh8nmvUk2mL9fYvhoNumzqaOEoB2vDs9uHHL6tGCZzRSKw3G0EevfGaY1wJlS4oA-_QfdpiXHms-wM8Y4KKpVpdiRcjmVktHfbkPBHOo1x3pNrdf8rNfsq-jJnzluJb_6rAA_AmV36A_z79n_sf0BlHS1Zw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2922307187</pqid></control><display><type>article</type><title>Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Sotani-Ogawa, Rei ; Kusuhara, Sentaro ; Hirota, Yushi ; Kim, Kyung Woo ; Matsumiya, Wataru ; Ogawa, Wataru ; Nakamura, Makoto</creator><creatorcontrib>Sotani-Ogawa, Rei ; Kusuhara, Sentaro ; Hirota, Yushi ; Kim, Kyung Woo ; Matsumiya, Wataru ; Ogawa, Wataru ; Nakamura, Makoto</creatorcontrib><description>Purpose
This pilot study aims to comprehensively evaluate the effects of sub-Tenon’s injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM).
Methods
This retrospective study analyzed changes in glycemic control in 20 patients with type 2 mellitus and DME following single STTA (20 mg/0.5 mL) using The FreeStyle Libre Pro system. Professional CGM provides core CGM metrics such as the percentage of time that glucose levels fall within a target range and include the time in range (TIR) (70–180 mg/dL), time above range (TAR) (> 180 mg/dL), and time below range (TBR) (< 70 mg/dL). Outcome measures were the changes in CGM metrics (TIR, TAR and TBR) and the percentage of patients in whom TAR increased by at least 10 percentage points (ppt) 4 days before to 4 days after STTA administration.
Results
The mean CGM metrics (TIR/TAR/TBR) were 75.5%/19.9%/4.4% 4 days before STTA and 73.7%/22.4%/3.5% 4 days after STTA; the metrics 4 days before and 4 days after STTA were not significantly different (
P
= 0.625 for TIR,
P
= 0.250 for TAR, and
P
= 0.375 for TBR). TAR increased by more than 10 ppt in four (20%) patients treated with sulfonylurea and/or insulin.
Conclusion
Although there were no significant changes in the CGM metrics, four patients developed CGM-measured hyperglycemia after STTA for DME.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-023-06275-y</identifier><identifier>PMID: 37864636</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Blood Glucose ; Blood Glucose Self-Monitoring ; Continuous Glucose Monitoring ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 1 ; Diabetic Retinopathy - complications ; Diabetic Retinopathy - diagnosis ; Diabetic Retinopathy - drug therapy ; Edema ; Glucocorticoids - adverse effects ; Glucose monitoring ; Humans ; Hyperglycemia ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - etiology ; Medicine ; Medicine & Public Health ; Ophthalmology ; Pilot Projects ; Retinal Disorders ; Retrospective Studies ; Sulfonylurea ; Triamcinolone Acetonide</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2024-02, Vol.262 (2), p.449-456</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c470t-d714372606fd5f41083ae7a1688df85a26577fed35a860840b0a3f637abd47cf3</cites><orcidid>0000-0002-6458-539X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00417-023-06275-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00417-023-06275-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37864636$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sotani-Ogawa, Rei</creatorcontrib><creatorcontrib>Kusuhara, Sentaro</creatorcontrib><creatorcontrib>Hirota, Yushi</creatorcontrib><creatorcontrib>Kim, Kyung Woo</creatorcontrib><creatorcontrib>Matsumiya, Wataru</creatorcontrib><creatorcontrib>Ogawa, Wataru</creatorcontrib><creatorcontrib>Nakamura, Makoto</creatorcontrib><title>Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Purpose
This pilot study aims to comprehensively evaluate the effects of sub-Tenon’s injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM).
Methods
This retrospective study analyzed changes in glycemic control in 20 patients with type 2 mellitus and DME following single STTA (20 mg/0.5 mL) using The FreeStyle Libre Pro system. Professional CGM provides core CGM metrics such as the percentage of time that glucose levels fall within a target range and include the time in range (TIR) (70–180 mg/dL), time above range (TAR) (> 180 mg/dL), and time below range (TBR) (< 70 mg/dL). Outcome measures were the changes in CGM metrics (TIR, TAR and TBR) and the percentage of patients in whom TAR increased by at least 10 percentage points (ppt) 4 days before to 4 days after STTA administration.
Results
The mean CGM metrics (TIR/TAR/TBR) were 75.5%/19.9%/4.4% 4 days before STTA and 73.7%/22.4%/3.5% 4 days after STTA; the metrics 4 days before and 4 days after STTA were not significantly different (
P
= 0.625 for TIR,
P
= 0.250 for TAR, and
P
= 0.375 for TBR). TAR increased by more than 10 ppt in four (20%) patients treated with sulfonylurea and/or insulin.
Conclusion
Although there were no significant changes in the CGM metrics, four patients developed CGM-measured hyperglycemia after STTA for DME.</description><subject>Blood Glucose</subject><subject>Blood Glucose Self-Monitoring</subject><subject>Continuous Glucose Monitoring</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 1</subject><subject>Diabetic Retinopathy - complications</subject><subject>Diabetic Retinopathy - diagnosis</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Edema</subject><subject>Glucocorticoids - adverse effects</subject><subject>Glucose monitoring</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Macular Edema - diagnosis</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - etiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Pilot Projects</subject><subject>Retinal Disorders</subject><subject>Retrospective Studies</subject><subject>Sulfonylurea</subject><subject>Triamcinolone Acetonide</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc2KFDEUhQtRnHb0BVxIwI2b0pufSjIrkcZRYcDNCLMLqdRNm6YqaZMqpReCrzGv55OYtsfxZ-EqkHzn3HtymuYxhecUQL0oAIKqFhhvQTLVtfs7zYoK3rUK2NXdZgWK0VZzdnXSPChlC5XnHb3fnHClpZBcrpqv6xTnEJe0FLIZF5cKkinFMKcc4oZMOOfgCvFpHNOXw01Z-vYSY4rfv10XEuIW3RxSJMmTitrJhZjGFJFYh3M1GrCKMxmC7XEOjkzWLaPNBAec7MPmnrdjwUc352nz4fz15fpte_H-zbv1q4vWCQVzO6iaSjEJ0g-dFxQ0t6gslVoPXneWyU4pjwPvrJagBfRguZdc2X4Qynl-2rw8-u6WfsLBYZyzHc0uh8nmvUk2mL9fYvhoNumzqaOEoB2vDs9uHHL6tGCZzRSKw3G0EevfGaY1wJlS4oA-_QfdpiXHms-wM8Y4KKpVpdiRcjmVktHfbkPBHOo1x3pNrdf8rNfsq-jJnzluJb_6rAA_AmV36A_z79n_sf0BlHS1Zw</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Sotani-Ogawa, Rei</creator><creator>Kusuhara, Sentaro</creator><creator>Hirota, Yushi</creator><creator>Kim, Kyung Woo</creator><creator>Matsumiya, Wataru</creator><creator>Ogawa, Wataru</creator><creator>Nakamura, Makoto</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6458-539X</orcidid></search><sort><creationdate>20240201</creationdate><title>Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema</title><author>Sotani-Ogawa, Rei ; Kusuhara, Sentaro ; Hirota, Yushi ; Kim, Kyung Woo ; Matsumiya, Wataru ; Ogawa, Wataru ; Nakamura, Makoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-d714372606fd5f41083ae7a1688df85a26577fed35a860840b0a3f637abd47cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Blood Glucose</topic><topic>Blood Glucose Self-Monitoring</topic><topic>Continuous Glucose Monitoring</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 1</topic><topic>Diabetic Retinopathy - complications</topic><topic>Diabetic Retinopathy - diagnosis</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Edema</topic><topic>Glucocorticoids - adverse effects</topic><topic>Glucose monitoring</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Macular Edema - diagnosis</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - etiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Pilot Projects</topic><topic>Retinal Disorders</topic><topic>Retrospective Studies</topic><topic>Sulfonylurea</topic><topic>Triamcinolone Acetonide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sotani-Ogawa, Rei</creatorcontrib><creatorcontrib>Kusuhara, Sentaro</creatorcontrib><creatorcontrib>Hirota, Yushi</creatorcontrib><creatorcontrib>Kim, Kyung Woo</creatorcontrib><creatorcontrib>Matsumiya, Wataru</creatorcontrib><creatorcontrib>Ogawa, Wataru</creatorcontrib><creatorcontrib>Nakamura, Makoto</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sotani-Ogawa, Rei</au><au>Kusuhara, Sentaro</au><au>Hirota, Yushi</au><au>Kim, Kyung Woo</au><au>Matsumiya, Wataru</au><au>Ogawa, Wataru</au><au>Nakamura, Makoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>262</volume><issue>2</issue><spage>449</spage><epage>456</epage><pages>449-456</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Purpose
This pilot study aims to comprehensively evaluate the effects of sub-Tenon’s injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM).
Methods
This retrospective study analyzed changes in glycemic control in 20 patients with type 2 mellitus and DME following single STTA (20 mg/0.5 mL) using The FreeStyle Libre Pro system. Professional CGM provides core CGM metrics such as the percentage of time that glucose levels fall within a target range and include the time in range (TIR) (70–180 mg/dL), time above range (TAR) (> 180 mg/dL), and time below range (TBR) (< 70 mg/dL). Outcome measures were the changes in CGM metrics (TIR, TAR and TBR) and the percentage of patients in whom TAR increased by at least 10 percentage points (ppt) 4 days before to 4 days after STTA administration.
Results
The mean CGM metrics (TIR/TAR/TBR) were 75.5%/19.9%/4.4% 4 days before STTA and 73.7%/22.4%/3.5% 4 days after STTA; the metrics 4 days before and 4 days after STTA were not significantly different (
P
= 0.625 for TIR,
P
= 0.250 for TAR, and
P
= 0.375 for TBR). TAR increased by more than 10 ppt in four (20%) patients treated with sulfonylurea and/or insulin.
Conclusion
Although there were no significant changes in the CGM metrics, four patients developed CGM-measured hyperglycemia after STTA for DME.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37864636</pmid><doi>10.1007/s00417-023-06275-y</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6458-539X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2024-02, Vol.262 (2), p.449-456 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10844153 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Blood Glucose Blood Glucose Self-Monitoring Continuous Glucose Monitoring Diabetes Diabetes mellitus Diabetes Mellitus, Type 1 Diabetic Retinopathy - complications Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Edema Glucocorticoids - adverse effects Glucose monitoring Humans Hyperglycemia Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - etiology Medicine Medicine & Public Health Ophthalmology Pilot Projects Retinal Disorders Retrospective Studies Sulfonylurea Triamcinolone Acetonide |
| title | Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T05%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20glucose%20monitoring%20metrics%20following%20sub-Tenon%E2%80%99s%20injection%20of%20triamcinolone%20acetonide%20for%20diabetic%20macular%20edema&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Sotani-Ogawa,%20Rei&rft.date=2024-02-01&rft.volume=262&rft.issue=2&rft.spage=449&rft.epage=456&rft.pages=449-456&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-023-06275-y&rft_dat=%3Cproquest_pubme%3E2922307187%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2922307187&rft_id=info:pmid/37864636&rfr_iscdi=true |